<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">31804</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Kidney injury associated with monoclonal gammopathies: Perspectives on diagnosis and treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Поражение почек, ассоциированное с моноклональными гаммапатиями: перспективы диагностики и лечения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlovskaya</surname><given-names>L V</given-names></name><name xml:lang="ru"><surname>Козловская</surname><given-names>Л В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rameev</surname><given-names>V V</given-names></name><name xml:lang="ru"><surname>Рамеев</surname><given-names>В В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mrykhin</surname><given-names>N N</given-names></name><name xml:lang="ru"><surname>Мрыхин</surname><given-names>Н Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kogarko</surname><given-names>I N</given-names></name><name xml:lang="ru"><surname>Когарко</surname><given-names>И Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kogarko</surname><given-names>B S</given-names></name><name xml:lang="ru"><surname>Когарко</surname><given-names>Б С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">«Первый МГМУ им. И.М. Сеченова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">«Институт химической физики им. Н.Н. Семенова» РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2015</year></pub-date><volume>87</volume><issue>6</issue><issue-title xml:lang="en">VOL 87, NO6 ()</issue-title><issue-title xml:lang="ru">ТОМ 87, №6 (2015)</issue-title><fpage>108</fpage><lpage>111</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/31804">https://ter-arkhiv.ru/0040-3660/article/view/31804</self-uri><abstract xml:lang="en"><p>It is currently well justified that monoclonal gammopathies are the most important predictor for kidney diseases, including glomerulonephritis. To determine a correlation of nephropathy with oligosecretory gammopathy is of fundamental importance, as the treatment of these patients necessitates the use of special chemotherapy regimens to eliminate a pathological clone of lymphocytes or plasmocytes. If this clone is not eliminated, injury of the organ may recur to develop its failure. The principles of this therapy have been presently tried out by the example of AL-amyloidosis and showed its efficiency and relatively low toxicity.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящее время хорошо обосновано, что моноклональные гаммапатии являются важнейшим прогностически значимым фактором развития заболеваний почек, в том числе гломерулонефрита. Выявление связи нефропатии с олигосекреторной гаммапатией имеет принципиальное значение, так как лечение таких больных обусловливает необходимость применения особых схем химиотерапии, направленных на элиминацию патологического клона лимфоцитов или плазмоцитов. Без элиминации этого клона органное поражение будет рецидивировать с развитием органной недостаточности. Принципы такой терапии в настоящее время хорошо отработаны на примере AL-амилоидоза, показали свою эффективность и относительно низкую токсичность.</p></trans-abstract><kwd-group xml:lang="en"><kwd>monoclonal gammopathies</kwd><kwd>amyloidosis</kwd><kwd>kidney diseases</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>моноклональные гаммапатии</kwd><kwd>амилоидоз</kwd><kwd>болезни почек</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-826.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. III Prevalence of Monoclonal Gammopathy of Undetermined Significance. NEJM. 2006;354:1362-1369.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10): 3960-3963.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bradwell AR. Serum free light chain analysis, 4th edition, 2006, The Binding Site Ltd.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154-1163.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis — the archetype of structural and pathogenic variability. J Struct Biol. 2000;130(2-3):280-289. Review.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801-3018.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84(4):440-451.</mixed-citation></ref></ref-list></back></article>
